MELLARIL-S Drug Patent Profile
✉ Email this page to a colleague
When do Mellaril-s patents expire, and what generic alternatives are available?
Mellaril-s is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in MELLARIL-S is thioridazine. There are eighteen drug master file entries for this compound. Additional details are available on the thioridazine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MELLARIL-S?
- What are the global sales for MELLARIL-S?
- What is Average Wholesale Price for MELLARIL-S?
Summary for MELLARIL-S
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,188 |
| DailyMed Link: | MELLARIL-S at DailyMed |
Recent Clinical Trials for MELLARIL-S
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| New Mexico Cancer Care Alliance | Early Phase 1 |
| Oxnard Foundation | Early Phase 1 |
US Patents and Regulatory Information for MELLARIL-S
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | MELLARIL-S | thioridazine | SUSPENSION;ORAL | 017923-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | MELLARIL-S | thioridazine | SUSPENSION;ORAL | 017923-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
